| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10907833 | Experimental Hematology | 2005 | 6 Pages |
Abstract
Our successful pilot trial suggests that positive selection of CD133+ stem cells may be a useful method for safe transplantation with haploidentically mismatched stem cell allografts while avoiding lethal acute and chronic GVHD. Future studies will be required to assess the clinical benefits of stem cell purification with CD133+ in comparison with CD34+ stem cells.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Menachem Bitan, Michael Y. Shapira, Igor B. Resnick, Irina Zilberman, Svetlana Miron, Simcha Samuel, Aliza Ackerstein, Sharon Elad, Shosh Israel, Avraham Amar, Eitan Fibach, Reuven Or, Shimon Slavin,